Medicus Reports Phase 1 Teverelix Data, Showing Rapid And Reversible Hormone Suppression; Highlight Favorable Safety And Bone Stability

Medicus Pharma has announced that detailed Phase 1 clinical data for Teverelix, its long-acting GnRH antagonist, have been accepted for e-Poster presentation at the AACE Annual Meeting 2026 in Las Vegas. The accepted abstract summarizes the results from two randomized, placebo-controlled studies in 48 healthy premenopausal women, evaluating the absorption of Teverelix, its effects on suppressing reproductive hormones, its impact on bone turnover, and its overall safety after a single injection.

The Phase 1 studies showed that Teverelix rapidly suppressed LH and FSH within 24 hours, with dose-dependent and reversible reductions in estradiol levels. At higher doses, hormone suppression was sustained for up to two to three weeks, while bone turnover markers remained stable, suggesting no short-term bone loss. The drug was generally well tolerated, with no serious treatment-related adverse events and only mild to moderate side effects reported.

“We believe that these findings reinforce the versatility of Teverelix as a long-acting GnRH antagonist platform,” stated Dr. Raza Bokhari, Medicus Exec. Chairman & CEO, “In addition to its development in prostate cancer and acute urinary retention relapse prevention, we believe these Phase 1 results support advancement into women’s health indication, endometriosis, a condition, affecting ~10% of women of reproductive age worldwide, where controlled, reversible hormone suppression and bone safety are critical. We are currently engaged in a regulatory planning for a Phase 2, Genomics-informed study of Teverelix in women with symptomatic endometriosis in United Arab Emirates (UAE)”.

Teverelix is a long-acting injectable GnRH antagonist that works by immediately blocking hormone receptors, avoiding the initial hormonal flare seen with GnRH agonists. This mechanism may be particularly relevant for patients such as those with advanced prostate cancer and elevated cardiovascular risk, as ongoing FSH exposure has been linked to cardiovascular complications. To date, no significant cardiovascular safety signals have been observed in Teverelix studies; however, further clinical validation is still needed.

Alongside Teverelix, Medicus continues to advance SkinJect™, its dissolvable microneedle platform delivering doxorubicin for non-invasive treatment of basal cell carcinoma. Phase 2 enrollment is complete, with topline data expected in the first quarter of 2026 and an FDA end-of-Phase 2 meeting planned for the first half of the year, supporting the company’s strategy of de-risking assets through Phase 2 and seeking strategic partnerships.